Cargando…

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

BACKGROUND: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have been associated with the increased likelihood of developing adverse CNS effects. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gounden, Verena, van Niekerk, Chantal, Snyman, Tracy, George, Jaya A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933581/ https://www.ncbi.nlm.nih.gov/pubmed/20723261 http://dx.doi.org/10.1186/1742-6405-7-32

Ejemplares similares

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

Efavirenz and neuropsychiatric effects
por: Dheda, Mukesh
Publicado: (2017)

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele
por: Bordin Andriguetti, Natália, et al.
Publicado: (2021)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

Perspectives of healthcare professionals of the neuropsychiatric side effects associated with efavirenz and its management
por: Gaida, Razia, et al.
Publicado: (2018)

Prevalence of MDR1 C3435T and CYP2B6 G516T Polymorphisms among HIV-1 Infected South African Patients
por: Masebe, Tracy Madimabi, et al.
Publicado: (2012)

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
por: Nightingale, Sam, et al.
Publicado: (2016)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Distribution of CYP2B6 516G/T pharmacogenetically important polymorphism in the Ukrainian population
por: Filiptsova, Olga, et al.
Publicado: (2018)

Occurrence of CYP2B6 516G>T polymorphism in patients with ARV‐associated hepatotoxicity
por: Singh, HariOm, et al.
Publicado: (2019)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz
por: Drury, Andrew, et al.
Publicado: (2018)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
por: Johnston, Jenna, et al.
Publicado: (2019)

Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape
por: Gaida, Razia, et al.
Publicado: (2016)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

The G(516)T CYP2B6 Germline Polymorphism Affects the Risk of Acute Myeloid Leukemia and Is Associated with Specific Chromosomal Abnormalities
por: Daraki, Aggeliki, et al.
Publicado: (2014)

An audit of immunofixation requesting practices at a South African referral laboratory
por: Gounden, Verena, et al.
Publicado: (2014)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

1033. One year of Bictegravir in Mexico City: Differences in the Neuropsychiatric Adverse Events vs. Efavirenz
por: Rodriguez, Victor
Publicado: (2020)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
por: Huang, Sung-Hsi, et al.
Publicado: (2017)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

THU516 An Unusual Neck Mass
por: Rios, Paola, et al.
Publicado: (2023)

PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
por: Swart, Marelize, et al.
Publicado: (2012)

Comparison of 24-hour versus random urine samples for determination and quantification of Bence Jones protein in a South African population
por: Reddy, Ashandree, et al.
Publicado: (2021)

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes
por: Abdullahi, Sa’ad T., et al.
Publicado: (2020)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
por: Chamnanphon, Monpat, et al.
Publicado: (2021)

Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa—A Retrospective Case Series
por: Hammond, Charles K., et al.
Publicado: (2019)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
por: Stellbrink, HJ, et al.
Publicado: (2010)

Efavirenz poisoning in a 12 year old HIV negative African boy
por: Nazziwa, Rose, et al.
Publicado: (2012)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ugddfjrg0ju9lnbhfb34itq60g